GlassScriptPhysician profile
Haojie Wang
NPI 1316107246
$16,796.05
in general payments reported to CMS, 2019-2025
23 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,117 · 2021: $90.77 · 2022: $208 · 2023: $397 · 2024: $254 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $15,000.00 | 2019-2020 | |
| Medtronic, INC. | $283.79 | 2023-2025 | Corevalve Evolut R, Symplicity G3, Claria Mri Quad Crt-D Surescan |
| E.R. Squibb & Sons, L.L.C. | $224.77 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $207.69 | 2019-2024 | |
| Amgen INC. | $191.40 | 2019-2025 | Repatha |
| Cleerly, INC. | $156.52 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Siemens Medical Solutions USA, INC. | $136.11 | 2024 | Magnetom Free.Max, Somatom Force |
| Amarin Pharma, INC. | $70.03 | 2019 | |
| Novo Nordisk INC | $65.64 | 2022-2024 | Ozempic |
| Janssen Pharmaceuticals, INC | $56.56 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $55.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.57 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $40.19 | 2021-2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $37.12 | 2020-2024 | |
| Tactile Systems Technology INC | $35.69 | 2023 | Flexitouch Plus, Entre Plus |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.73 | 2020-2021 | |
| Ge Healthcare | $30.10 | 2025 | |
| Merck Sharp & Dohme LLC | $26.11 | 2023 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $25.94 | 2024 | Alunbrig |
| W. L. Gore & Associates, INC. | $19.49 | 2019 | |
| Edwards Lifesciences Corporation | $18.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.11 | 2023 | Evkeeza, Praluent |
| Astrazeneca Pharmaceuticals LP | $13.41 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haojie Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.